


PHARMACEUTICAL 2021

GALECTIN THERAPEUTICS INC Rank 328 of 409







PHARMACEUTICAL 2021

GALECTIN THERAPEUTICS INC Rank 328 of 409

The relative strengths and weaknesses of GALECTIN THERAPEUTICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GALECTIN THERAPEUTICS INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 94% points. The greatest weakness of GALECTIN THERAPEUTICS INC is the variable Net Income, reducing the Economic Capital Ratio by 254% points.

The company's Economic Capital Ratio, given in the ranking table, is -392%, being 38% points below the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	29,465
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,399
Liabilities, Non-Current	8.0
Other Assets	135
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-21
Property and Equipment	0
Research and Development	17,976
Revenues	0
Selling, General and Administrative Expense	5,468

Output Variable	Value in 1000 USD
Assets	29,600
Liabilities	5,407
Expenses	23,444
Stockholders Equity	24,193
Net Income	-23,465
Comprehensive Net Income	-23,465
Economic Capital Ratio	-392%

